Helio Genomics Methylation Model Score for Early Cancer Detection Awarded as a Top Abstract for the 2024 San Antonio Liver Cancer Symposium


IRVINE, Calif., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Helio Genomics (“Helio” or “the Company”), an AI-driven healthcare company specializing in diagnostics technology and test development for cancer detection, today announced that its abstract entitled “Cell-free DNA methylation biomarkers for evaluating prognosis and treatment response in patients with hepatocellular carcinoma”, was selected as one of the top three abstracts, and as a poster presentation, at the 2024 San Antonio Liver Cancer Symposium, to be held at the Hilton Palacio del Rio in San Antonio, Texas from October 11–12, 2024. This study was conducted in collaboration with Ochsner Health.

Original post:
Helio Genomics Methylation Model Score for Early Cancer Detection Awarded as a Top Abstract for the 2024 San Antonio Liver Cancer Symposium

Related Posts